<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Propylthiouracil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Propylthiouracil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Propylthiouracil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11006" href="/d/html/11006.html" rel="external">see "Propylthiouracil: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12745" href="/d/html/12745.html" rel="external">see "Propylthiouracil: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F10163904"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Reserve propylthiouracil for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868066"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Halycil;</li>
<li>Propyl-Thyracil [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F215099"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antithyroid Agent;</li>
<li>
                        Thioamide</li></ul></div>
<div class="block doa drugH1Div" id="F215076"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="635b4491-18d8-4a22-94bc-de8c22e8f36c">Hyperthyroidism associated with Graves disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism associated with Graves disease:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Preferred over methimazole during the first trimester of pregnancy; may also be used as chronic low-dose treatment in patients who have minor skin reactions to methimazole (eg, rash, hives) and do not wish to undergo definitive therapy (ie, radioactive iodine therapy or surgery) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Use during pregnancy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: 50 mg 2 to 3 times daily; doses up to 300 mg/day may be required in patients with severe hyperthyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from methimazole therapy:</i> 5 mg of methimazole is equivalent to ~100 mg of propylthiouracil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690','lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690','lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosage adjustment:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Adjust dose based on thyroid function tests obtained every 4 weeks to maintain serum free T<sub>4</sub> concentration at or just above the ULN (using a trimester-specific reference range) and serum TSH concentrations below the reference range for pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Usual maintenance dose: <b>Oral: </b>≤50 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: After 16 weeks’ gestation, may switch to methimazole or continue propylthiouracil based on shared decision-making with the patient; may consider discontinuation of antithyroid drug therapy during the third trimester of pregnancy based on thyroid function tests and TSH-receptor antibody levels. Continue to monitor TSH and free or total T<sub>4</sub> throughout pregnancy and in the postpartum period; Graves disease often worsens postpartum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690','lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690','lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Use in nonpregnant patients (eg, patients who have minor skin reactions to methimazole):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial dosage: <b>Oral:</b> 50 to 150 mg 3 times daily; doses up to 800 mg/day may be required in patients with severe hyperthyroidism (eg, free T<sub>4</sub> ≥2 times ULN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-30320502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-30320502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from methimazole therapy:</i> 5 mg of methimazole is equivalent to ~100 mg of propylthiouracil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosage adjustment: <b>Oral:</b> Usual maintenance dose: 50 mg 2 to 3 times daily (ATA [Ross 2016]). Assess free T<sub>4</sub> and total T<sub>3</sub> at 4- to 6-week intervals; gradually adjust dose to achieve euthyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients undergoing definitive therapy:</i> Prior to definitive therapy, continue until euthyroid (typically 4 to 6 weeks); discontinue 2 to 3 days before radioactive iodine therapy or on the day of thyroidectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients not undergoing definitive therapy:</i> Continue therapy for a total of ~12 to 18 months, then assess for remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a41aff3c-8618-4d56-b4f4-9502cf751d29">Hyperthyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism:</b>
<b>Oral:</b> Initial: 300 mg daily in 3 equally divided doses (~8-hour intervals); 400 mg daily in patients with severe hyperthyroidism and/or very large goiters; an occasional patient will require 600 to 900 mg daily; usual maintenance: 100 to 150 mg daily in 3 equally divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Adjust dosage as required to achieve and maintain serum T<sub>3,</sub> T<sub>4</sub>, and TSH levels in the normal range. An elevated T<sub>3</sub> may be the sole indicator of inadequate treatment. An elevated TSH indicates excessive antithyroid treatment.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="047533da-224f-4a4b-80a0-828eaed715da">Internal contamination with radioactive iodine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Internal contamination with radioactive iodine (I-131) (off-label use): </b>Use may be considered if potassium iodide is unavailable, contraindicated, or unlikely to be effective (eg, too late for potassium iodide to be effective). In patients &gt;40 years of age, treatment for inhalational exposure to radioactive iodine is not recommended unless the projected thyroid dose is &gt;5 sievert (Sv) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-REMM.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-REMM.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 100 mg 3 times daily for 8 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-REMM.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-REMM.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (off-label use):</b>
<b>Note: </b>Use in combination with other appropriate agents; if iodine is administered, delay iodine administration by ≥1 hour after propylthiouracil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg to 1 g loading dose, followed by 200 to 250 mg every 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.3'])">Ref</a></span>); some experts do not administer a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.3'])">Ref</a></span>). Once clinically stable, switch to methimazole; in patients with minor skin reactions to methimazole (eg, rash, hives), may gradually reduce propylthiouracil dose (eg, to 100 to 600 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-14710692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-14710692'])">Ref</a></span>). In patients who cannot take propylthiouracil by mouth, alternative administration routes (eg, nasogastric, rectal) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12193309','lexi-content-ref-17127140','lexi-content-ref-8563481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12193309','lexi-content-ref-17127140','lexi-content-ref-8563481'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991425"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988696"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F50472661"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F215088"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12745" href="/d/html/12745.html" rel="external">see "Propylthiouracil: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to reports of severe liver toxicity, propylthiouracil is not recommended for use in pediatric patients; use should be limited to patients who have developed minor toxic reactions to methimazole and who are not candidates for surgery or radioactive iodine treatment. If use deemed necessary, patients and parents should be informed of risks and propylthiouracil therapy limited to a short course with close patient monitoring (eg, baseline CBC, liver profile including LFTs, bilirubin, and alkaline phosphatase recommended). Discontinue therapy at first sign of hepatotoxicity and initiate hepatic assessment (see "Dosing: Hepatic Impairment: Pediatric") (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32ab66a1-fee8-429f-ab7f-38a944ff2682">Hyperthyroidism, alternate therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism, alternate therapy:</b>
<b>Note: </b>Adjust dosage to maintain T<sub>3</sub>, T<sub>4</sub>, and thyroid stimulating hormone (TSH) in normal range; elevated T<sub>3</sub> may be sole indicator of inadequate treatment. Elevated TSH indicates excessive antithyroid treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: ≥6 years and Adolescents: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Paladin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Paladin.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial:</p>
<p style="text-indent:-2em;margin-left:8em;">BSA-directed dosing: Oral: 150 mg/m<sup>2</sup>/day in divided doses every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Age-directed fixed dosing:</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 10 years: Oral: 50 to 150 mg/day divided every 8 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">≥10 years: Oral: 150 to 300 mg/day divided every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (once euthyroid): Dose should be individualized based on patient response: Oral: Usual dose: 50 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage</b>
<b> adjustment for toxicity:</b> Discontinue use for signs of infection (fever, arthralgias, mouth sores, pharyngitis, or malaise); assess WBC count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51159512"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159513"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Due to reports of severe liver toxicity, propylthiouracil is not recommended for use in pediatric patients. If used, limit duration to short course of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline hepatic impairment: </i>ALT or AST &gt;5 x ULN: Reconsider initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment: </i>Discontinue therapy at first sign of liver injury (eg, anorexia, pruritus, rash, jaundice, light stool, dark urine, joint pain, right upper quadrant pain, abdominal bloating, nausea, malaise) and assess LFTs. Permanently discontinue if AST or ALT 2 to 3 times ULN fails to resolve within a week of repeat testing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F215040"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic: Agranulocytosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, skin pigmentation, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, dysgeusia, epigastric discomfort, nausea, salivary gland disease, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, headache, neuritis, paresthesia, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity angiitis, periarteritis, vasculitis (ANCA-positive and cerebral)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema nodosum, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ischemic colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, granulocytopenia, hemorrhage, hypoprothrombinemia, splenomegaly, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (including acute hepatic failure), hepatic injury (severe), hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug fever</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis, nephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pulmonary alveolar hemorrhage</p></div>
<div class="block coi drugH1Div" id="F215054"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to propylthiouracil or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Breastfeeding</p></div>
<div class="block war drugH1Div" id="F215037"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: May cause hypoprothrombinemia and bleeding. Monitoring is recommended, especially before surgical procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: May cause significant bone marrow depression; the most severe manifestation is agranulocytosis (usually occurs within first 3 months of therapy). Aplastic anemia (Shaikh 2019), thrombocytopenia, and leukopenia may also occur. Use with caution in patients receiving other drugs known to cause myelosuppression (particularly agranulocytosis); discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: May occur; discontinue in the presence of exfoliative dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fever: Discontinue in the presence of unexplained fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: <b>[US Boxed Warning]: Severe liver injury and acute liver failure (some fatal) have been reported and have included cases requiring liver transplantation in adult and pediatric patients, including pregnant women. Reserve propylthiouracil for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism.</b> Current guidelines suggest that propylthiouracil may be preferred over methimazole during the first trimester of pregnancy (ATA [Alexander 2017]; ATA [Ross 2016]). Routine LFT monitoring may not reduce risk due to unpredictable and rapid onset. Patients should be counseled to recognize and report symptoms suggestive of hepatic dysfunction (eg, anorexia, pruritus, right upper quadrant pain), especially in first 6 months of treatment, which should prompt immediate discontinuation. Discontinue therapy if transaminases are &gt;3 times the ULN or if levels elevated at the onset of therapy increase further (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T<sub>4</sub> levels, adjust dose to maintain euthyroid state.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lupus-like syndrome: A lupus-like syndrome (including splenomegaly and vasculitis) may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephritis: Has been associated with nephritis and glomerulonephritis, sometimes leading to acute renal failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pneumonitis: Interstitial pneumonitis has been reported; discontinue if this reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasculitis: Cases of vasculitis resulting in severe complications and death have been reported. Most cases were ANCA-positive and included alveolar/pulmonary hemorrhage, cerebral angiitis, glomerulonephritis, ischemic colitis, and leukocytoclastic cutaneous vasculitis. Discontinue use for confirmed or suspected vasculitis. Some cases resolve/improve with drug discontinuation; severe cases may require further treatment (eg, corticosteroids, immunosuppressant therapy, plasmapheresis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878612"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients, severe liver injury including hepatic failure requiring transplantation or resulting in death have been reported with propylthiouracil (most cases with doses ≥300 mg, but has also been reported with the lower 50 mg dose). Routine liver function test monitoring may not reduce risk due to unpredictable and rapid onset. Use is not recommended and should be limited to patients who have developed minor toxic reactions to methimazole and who are not candidates for surgery or radioactive iodine treatment. If use necessary, patients and parents should be informed of risks and propylthiouracil therapy limited to a short course with close patient monitoring (baseline CBC, liver profile including LFTs, bilirubin, and alkaline phosphatase recommended). Discontinue use, contact prescriber, and obtain CBC (WBC) and LFTs (transaminases) if any of the following occur: Tiredness, nausea, anorexia, fever, pharyngitis, malaise, pruritus, rash, jaundice, light-colored stool or dark urine, joint pain, right upper quadrant pain, abdominal bloating (ATA [Ross 2016]).</p></div>
<div class="block foc drugH1Div" id="F215047"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F215033"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F215057"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Propylthiouracil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868067"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Halycil: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Propyl-Thyracil: 50 mg [DSC], 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block adm drugH1Div" id="F9603933"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasogastric:</b> In thyroid storm, nasogastric administration has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17127140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17127140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer in 3 equally divided doses at approximately 8-hour intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> In thyroid storm, rectal administration has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12193309','lexi-content-ref-8563481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12193309','lexi-content-ref-8563481'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613725"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer in 3 equally divided doses at approximately 8-hour intervals.</p></div>
<div class="block hazard drugH1Div" id="F49132821"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block meg drugH1Div" id="F10162707"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F006188s026lbl.pdf%23page%3D7&amp;token=VBNfmueocSeVrkZFcGLtB4sD%2FKRObDcA29vTVbdch3gFUEEI1xW8lJrmP93JcvbSAxgSwtpuXDLB1qKZtboB7QOLRvGyW07sBUetp7Tk2ZkzZBugMjtAKaQhPScPKw4P&amp;TOPIC_ID=9830" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006188s026lbl.pdf#page=7</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F215050"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperthyroidism:</b> Treatment of hyperthyroidism in patients with Graves disease or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment regimen; amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy (in patients who are intolerant of methimazole).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Current guidelines suggest that propylthiouracil may be preferred over methimazole during the first trimester of pregnancy (ATA [Alexander 2017]; ATA [Ross 2016]).</p></div>
<div class="block off-label drugH1Div" id="F50472659"><span class="drugH1">Use: Off-Label: Adult</span><p>Internal contamination with radioactive iodine (I-131); Thyroid storm</p></div>
<div class="block mst drugH1Div" id="F215107"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Propylthiouracil may be confused with Purinethol [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">PTU is an error-prone abbreviation (mistaken as mercaptopurine [Purinethol; 6-MP])</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299953"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F215042"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Propylthiouracil may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antithyroid Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antithyroid agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid medications at least 3 days before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52928906"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients taking propylthiouracil should use effective contraception and postpone becoming pregnant until a stable euthyroid state is achieved. Unless otherwise contraindicated, propylthiouracil may be the preferred treatment when an antithyroid drug is indicated just prior to the first trimester of pregnancy. Patients taking propylthiouracil should notify their health care provider immediately once pregnancy is suspected. The decision to continue antithyroid medications during pregnancy should be individualized (ATA [Alexander 2017]).</p></div>
<div class="block pri drugH1Div" id="F215058"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Propylthiouracil crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse events associated with propylthiouracil use during pregnancy include liver damage in the mother and fetus and hypothyroidism in the fetus/neonate. Face and neck cysts and urinary tract abnormalities in male offspring have also been reported (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled maternal hyperthyroidism may result in adverse neonatal and maternal outcomes. Adverse outcomes associated with poorly controlled thyrotoxicosis include pregnancy loss, pregnancy-induced hypertension, maternal congestive heart failure, and thyroid storm, as well as prematurity, low birth weight, intrauterine growth restriction, and stillbirth (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetic properties of propylthiouracil are not significantly changed by pregnancy; however, the severity of hyperthyroidism may fluctuate throughout pregnancy (Clark 2006; Sitar 1979; Sitar 1982). If a euthyroid state is maintained, doses of propylthiouracil may be decreased as pregnancy progresses and discontinued weeks to months prior to delivery.</p>
<p style="text-indent:0em;margin-top:2em;">To avoid potential adverse effects, antithyroid drugs may be discontinued as soon as pregnancy is detected in select patients with well-controlled Graves disease at low risk for relapse; close monitoring of maternal and fetal thyroid function is recommended (ATA [Alexander 2017]). When treatment is necessary, antithyroid drugs are the treatment of choice for the control of hyperthyroidism during pregnancy (ACOG 2020; ATA [Alexander 2017]). Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during the first 16 weeks of pregnancy. Due to the potential for hepatic toxicity, other antithyroid medications could be considered after 16 weeks' gestation (ATA [Alexander 2017]). To prevent adverse outcomes, the lowest effective dose should be used to keep the maternal TT4/FT4 at or just above the pregnancy-specific ULN. Propylthiouracil may be used for the treatment of thyroid storm in pregnant patients (ACOG 2020; ATA [Alexander 2017]).</p></div>
<div class="block brc drugH1Div" id="F5270920"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Propylthiouracil is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of propylthiouracil in breast milk is available from 9 euthyroid breastfeeding women (2 with Graves disease) at 1 to 8 months postpartum. Propylthiouracil 400 mg was administered as a single dose and drug concentrations in maternal serum and breast milk were measured every 30 minutes for 4 hours. The mean maternal serum concentration at 90 minutes was 7.7 ± 1 mcg/mL and decreased to 3.9 ± 0.5 mcg/mL after 4 hours. The mean propylthiouracil concentration in milk at 90 minutes was 0.7 ± 0.2 mcg/mL and decreased to 0.5 ± 0.1 mcg/mL after 4 hours. The mean volume of milk collected in 4 hours contained propylthiouracil equivalent to 0.025% of the ingested dose. The authors calculated that a 3.5 kg infant would receive a dose equivalent to 3 mg (range: 0.8 to 9.2 mg) for a 70 kg adult and it is unlikely to affect infant thyroid hormone metabolism (Kampmann 1980). Using a mean milk concentration of 0.7 mcg/mL, the estimated exposure to the breastfeeding infant would be 0.11 mg/kg/day (relative infant dose [RID] &lt;2% based on a weight adjusted maternal dose of 400 mg/day). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Based on available data, thyroid function is normal in infants exposed to propylthiouracil via breast milk. The treatment of hyperthyroidism in breastfeeding patients is the same as non-breastfeeding patients. Maternal use of propylthiouracil is considered acceptable while breastfeeding (ATA [Alexander 2017]; WHO 2002) although it may not be preferred due to the potential risk of maternal hepatic toxicity (Amino 2020). The lowest effective dose should be used; maternal doses of propylthiouracil ≤450 mg/day are advised in breastfeeding patients. Infants exposed to antithyroid medications via breast milk should be monitored for adequate growth and development; routine tests of thyroid function are not recommended (ATA [Alexander 2017]). Taking the dose of propylthiouracil after breastfeeding may help decrease potential infant exposure by providing a 3- to 4-hour interval before the next feed (Amino 2020).</p></div>
<div class="block mop drugH1Div" id="F215045"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Signs and symptoms of illness (ie fever, sore throat, skin eruptions, general malaise) or vasculitis.</p>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (baseline and if development of febrile illness or pharyngitis occurs); prothrombin time (especially before surgical procedures), LFTs (bilirubin, alkaline phosphatase, ALT, AST at baseline and if symptoms of liver injury occur) (ATA [Ross 2016]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid function tests:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum free T<sub>4</sub> and total T<sub>3</sub> at 4- to 6-week intervals during dose titration, then every 2 to 3 months once euthyroid levels are achieved; with long-term therapy (ie, &gt;18 months) may extend interval to every 4 to 6 months. In patients with Graves disease, if thyrotropin receptor autoantibodies (TRAbs) are negative, thyroid function tests should be monitored every 2 to 3 months for the first 6 months after discontinuing therapy, then at 4- to 6-month intervals for the next 6 months, then every 6 to 12 months thereafter (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Thyroid stimulating hormone (TSH) periodically throughout treatment; TSH is not an adequate parameter to assess initial response as levels may remain suppressed for several months after starting therapy (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">TRAb in patients with Graves disease prior to stopping medication, elevation at the end of therapy decreases likelihood of remission (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnant patients: Free T<sub>4</sub> and total T<sub>3</sub> every 2 to 4 weeks until stabilized (ACOG 2020). Free T<sub>4</sub>, total T<sub>4</sub>, and TSH approximately every 4 weeks throughout pregnancy. TRAb once pregnancy is confirmed, at 18 to 22 weeks' gestation, and 30 to 34 weeks' gestation (ATA [Alexander 2017]).</p></div>
<div class="block rer drugH1Div" id="F215048"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Normal laboratory values:</p>
<p style="text-indent:-2em;margin-left:2em;">Total T<sub>4</sub>: 5 to 12 mcg/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Serum T<sub>3</sub>: 90 to 185 ng/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Free thyroxine index (FT<sub>4</sub> I): 6 to 10.5</p>
<p style="text-indent:-2em;margin-left:2em;">TSH: 0.5 to 4.0 microunits/mL</p>
<p style="text-indent:-2em;margin-left:2em;">TRAb: &lt;1.75 int. units/L</p></div>
<div class="block pha drugH1Div" id="F215036"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits the synthesis of thyroid hormones by interfering with thyroid peroxidase (TPO) which oxidizes iodide, subsequently catalyzes formation of mono- and di-iodotyrosines (MIT and DIT) on thyroglobulin, and catalyzes coupling reactions between MIT and DIT to form thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) (Burch 2015); also blocks conversion of T<sub>4</sub> to T<sub>3</sub> in peripheral tissues (does not inactivate existing T<sub>4</sub> and T<sub>3</sub> stores in circulating blood and the thyroid and does not interfere with replacement thyroid hormones). Propylthiouracil also acts as a thyroid blocker to decrease the retention of radioactive iodine (I-131) into the thyroid (REMM 2022b).</p></div>
<div class="block phk drugH1Div" id="F215053"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: For significant therapeutic effects 24 to 36 hours are required; remission of hyperthyroidism usually does not occur before 4 months of continued therapy </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 12 to 24 hours (Clark 2006) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Concentrated in the thyroid gland (Clark 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 80% to 85% (Clark 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 53% to 88% (Clark 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~1 hour (Clark 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 2 hours (Clark 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (35%; primarily as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038787"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Prothiucil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Propylthiorit | Propylthiouracile christiaens</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Propil | Propilracil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Propycil | Propyl Thiouracil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Propiltiouracilo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao kang xin | Bing sai you</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tirostat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bocin-T | Ptu</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Tirostat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Propycil | Thyrosan | Tiotil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Thyrocil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Propycil | Propylex | Propylthiouracile ap-hp</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Propylthiourcl | Propylthiuracil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Propylthiouracile | Prothuril</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cp Ptu</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Propiltiouracil Alkaloid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Propiltiourasil | Ptu</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Propylthiocil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ptu</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Propacil | Thiuragyl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antiroid | Propacil | Propylthiourac</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Propycil | Thyreostat ii | Tiotil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Propyl</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Propylthiourac | Propylthiouracil Apotex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Propyltiouracil naf krageroe</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rhea propylthiouracil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Procarbizole</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Propycil | Thyrosan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Propyl Thiouracil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Propicil | Propycil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Thyrocil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tiotil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Propyl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Propilthiouracil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Peteyu | Propyl | Propyl Thiouracil | Pyroid | Thyrostat</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Propycil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Polupi | Procil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Propil Tiouracilo | Propiltiouracilo | Ptu</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tirostat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Propyl Thiouracil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. <i>Thyroid</i>. 2017;27(3):315-389. doi:10.1089/thy.2016.0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16887463">
<a name="16887463"></a>Aloush V, Litinsky I, Caspi D, et al. Propylthiouracil-Induced Autoimmune Syndromes: Two Distinct Clinical Presentations With Different Course and Management. <i>Semin Arthritis Rheum</i>. 2006;36(1):4-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/16887463/pubmed" id="16887463" target="_blank">16887463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics (AAP) Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 223: Thyroid disease in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32651061">
<a name="32651061"></a>Amino N, Arata N. Thyroid dysfunction following pregnancy and implications for breastfeeding. <i>Best Pract Res Clin Endocrinol Metab</i>. 2020;34(4):101438. doi:10.1016/j.beem.2020.101438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/32651061/pubmed" id="32651061" target="_blank">32651061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26670972">
<a name="26670972"></a>Burch HB, Cooper DS. Management of graves disease: a review. <i>JAMA</i>. 2015;314(23):2544-2554. doi:10.1001/jama.2015.16535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/26670972/pubmed" id="26670972" target="_blank">26670972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30320502">
<a name="30320502"></a>Burch HB, Cooper DS. Anniversary review: antithyroid drug therapy: 70 years later. <i>Eur J Endocrinol</i>. 2018;179(5):R261-R274. doi:10.1530/EJE-18-0678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/30320502/pubmed" id="30320502" target="_blank">30320502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449121">
<a name="16449121"></a>Casey BM, Dashe JS, Wells CE, et al. Subclinical Hyperthyroidism and Pregnancy Outcomes. <i>Obstet Gynecol</i>. 2006;107(2, pt 1):337-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/16449121/pubmed" id="16449121" target="_blank">16449121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11242611">
<a name="11242611"></a>Casis FC, Perez JB. Leukocytoclastic Vasculitis: A Rare Manifestation of Propylthiouracil Allergy. <i>Endocr Pract</i>. 2000;6(4):329-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/11242611/pubmed" id="11242611" target="_blank">11242611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16885714">
<a name="16885714"></a>Clark SM, Saade GR, Snodgrass WR, et al. Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy. <i>Ther Drug Monit</i>. 2006;28(4):477-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/16885714/pubmed" id="16885714" target="_blank">16885714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.1">
<a name="Cloherty.1"></a>Cloherty JP, Eichenwald EC, Martin CR, eds. <i>Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15745981">
<a name="15745981"></a>Cooper DS. Antithyroid Drugs. <i>N Engl J Med</i>. 2005;352(9):905-917.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/15745981/pubmed" id="15745981" target="_blank">15745981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11835230">
<a name="11835230"></a>Diav-Citrin O, Ornoy A. Teratogen Update: Antithyroid Drugs − Methimazole, Carbimazole, and Propylthiouracil. <i>Teratology</i>. 2002;65(1):38-44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/11835230/pubmed" id="11835230" target="_blank">11835230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12390348">
<a name="12390348"></a>Erten Y, Bodur H, Sahiner S, et al. Antineutrophil Cytoplasmic Antibody Associated Vasculitis and Rapidly Progressive Glomerulonephritis as a Complication of Propylthiouracil Therapy. <i>Clin Endocrinol (Oxf)</i>. 2002;57(5):699-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/12390348/pubmed" id="12390348" target="_blank">12390348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14710692">
<a name="14710692"></a>Goldberg PA, Inzucchi SE.Critical Issues in Endocrinology. <i>Clin Chest Med</i>. 2003;24(4):583-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/14710692/pubmed" id="14710692" target="_blank">14710692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9773944">
<a name="9773944"></a>Ichiki Y, Akahoshi M, Yamashita N, et al. Propylthiouracil-Induced Severe Hepatitis: A Case Report and Review of the Literature. <i>J Gastroenterol</i>. 1998;33(5):747-750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/9773944/pubmed" id="9773944" target="_blank">9773944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Johnson.1">
<a name="Johnson.1"></a>Johnson DG, Campbell S. Hormonal and metabolic agents. In: Bressler R, Katz MD, eds. <i>Geriatric Pharmacology</i>. McGraw-Hill; 1993:427-450.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12193309">
<a name="12193309"></a>Jongjaroenprasert W, Akarawut W, Chantasart D, Chailurkit L, Rajatanavin R. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. <i>Thyroid</i>. 2002;12(7):627-631. doi:10.1089/105072502320288500</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6103158">
<a name="6103158"></a>Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil in human milk. Revision of a dogma. <i>Lancet.</i> 1980;1(8171):736-737. doi:10.1016/s0140-6736(80)91233-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/6103158/pubmed" id="6103158" target="_blank">6103158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16418686">
<a name="16418686"></a>Koren G, Soldin O. Therapeutic Drug Monitoring of Antithyroid Drugs in Pregnancy: The Knowledge Gaps. <i>Ther Drug Monit</i>. 2006;28(1):12-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/16418686/pubmed" id="16418686" target="_blank">16418686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10878145">
<a name="10878145"></a>Lee A, Moretti, ME, Collantes A, et al. Choice of Breastfeeding and Physicians' Advice: A Cohort Study of Women Receiving Propylthiouracil. <i>Pediatrics</i>. 2000;106(1, pt 1):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/10878145/pubmed" id="10878145" target="_blank">10878145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8439116">
<a name="8439116"></a>Liaw YF, Huang MJ, Fan KD, et al. Hepatic Injury During Propylthiouracil Therapy in Patients With Hyperthyroidism. A Cohort Study. <i>Ann Intern Med</i>. 1993;118(6):424-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/8439116/pubmed" id="8439116" target="_blank">8439116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3812421">
<a name="3812421"></a>Limaye A, Ruffolo R. Propylthiouracil-Induced Fatal Hepatic Necrosis. <i>Am J Gastroenterol</i>. 1987;82(2):152-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/3812421/pubmed" id="3812421" target="_blank">3812421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9252857">
<a name="9252857"></a>Lock DR, Sthoeger ZM. Severe Hepatotoxicity on Beginning Propylthiouracil Therapy. <i>J Clin Gastroenterol</i>. 1997;24(4):267-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/9252857/pubmed" id="9252857" target="_blank">9252857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11397822">
<a name="11397822"></a>Mandel SJ, Cooper DS. The Use of Antithyroid Drugs in Pregnancy and Lactation. <i>J Clin Endocrinol Metab.</i> 2001;86(6):2354-2359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/11397822/pubmed" id="11397822" target="_blank">11397822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1261772">
<a name="1261772"></a>Mihas AA, Holley P, Koff RS, et al. Fulminant Hepatitis and Lymphocyte Sensitization Due to Propylthiouracil. <i>Gastroenterology</i>. 1976;70(5, pt 1):770-774.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/1261772/pubmed" id="1261772" target="_blank">1261772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and thyroid storm. <i>Endocrinol Metab Clin North Am</i>. 2006;35(4):663-686, vii. doi:10.1016/j.ecl.2006.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15251752">
<a name="15251752"></a>Nguyen LT, Luong KV, Pham BV. An Antineutrophil Cytoplasmic Autoantibody Associated With a Propylthiouracil-Induced Adult Respiratory Distress-Like Syndrome: Report of a Case and Review of the Literature. <i>Endocr Pract</i>. 1998;4(2):89-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/15251752/pubmed" id="15251752" target="_blank">15251752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10501437">
<a name="10501437"></a>Park KE, Chipps DR, Benson EM. Necrotizing Vasculitis Secondary to Propylthiouracil Presenting as Purpura Fulminans. <i>Rheumatology (Oxford)</i>. 1999;38(8):790-792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/10501437/pubmed" id="10501437" target="_blank">10501437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12052596">
<a name="12052596"></a>Peleg D, Cada S, Peleg A, et al. The Relationship Between Maternal Serum Thyroid-Stimulating Immunoglobulin and Fetal and Neonatal Thyrotoxicosis. <i>Obstet Gynecol</i>. 2002;99(6):1040-1043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/12052596/pubmed" id="12052596" target="_blank">12052596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Propylthiouracil tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paladin.1">
<a name="Paladin.1"></a>Propyl-Thyracil (propylthiouracil) [product monograph]. Saint-Laurent, Quebec, Canada; Paladin Labs Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paladin.2">
<a name="Paladin.2"></a>Propyl-Thyracil (propylthiouracil) [product monograph]. Montreal, Quebec, Canada; Paladin Labs; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1689656">
<a name="1689656"></a>Raby C, Lagorce JF, Jambut-Absil AC, et al. The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide. <i>Endocrinology</i>. 1990;126(3):1683-1691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/1689656/pubmed" id="1689656" target="_blank">1689656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REACTS.1">
<a name="REACTS.1"></a>Radiation Emergency Assistance Center/Training Site (REAC/TS). The medical aspects of radiation incidents. 4th ed. 2017. <a href="https://orise.orau.gov/resources/reacts/documents/medical-aspects-of-radiation-incidents.pdf" target="_blank">https://orise.orau.gov/resources/reacts/documents/medical-aspects-of-radiation-incidents.pdf</a>. Updated July 2017. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7791200">
<a name="7791200"></a>Romas E, Henderson DR, Kirkham BW.Propylthiouracil Therapy: An Unusual Cause of Antineutrophil Cytoplasmic Antibody Associated Alveolar Hemorrhage. <i>J Rheumatol</i>. 1995;22(4):803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/7791200/pubmed" id="7791200" target="_blank">7791200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.3">
<a name="Ross.3"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Hyperthyroidism during pregnancy: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 8, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.2">
<a name="Ross.2"></a>Ross DS. Thionamides in the treatment of Graves' disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12549953">
<a name="12549953"></a>Ruiz JK, Rossi GV, Vallejos HA, et al. Fulminant Hepatic Failure Associated With Propylthiouracil. <i>Ann Pharmacother</i>. 2003;37(2):224-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/12549953/pubmed" id="12549953" target="_blank">12549953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29357782">
<a name="29357782"></a>Shaikh H, Kamran A, Shaikh S, Mewawalla P. Aplastic anemia secondary to propylthiouracil: a rare and life-threatening adverse effect. <i>J Oncol Pharm Pract</i>. 2019;25(3):715-718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/29357782/pubmed" id="29357782" target="_blank">29357782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16847204">
<a name="16847204"></a>Sheen YS, Chu CY, Yu HS.Antineutrophil Cytoplasmic Antibody-Positive Cutaneous Leukocytoclastic Vasculitis Associated With Propylthiouracil Therapy. <i>Arch Dermatol</i>. 2006;142(7):879-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/16847204/pubmed" id="16847204" target="_blank">16847204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7122691">
<a name="7122691"></a>Sitar DS, Abu-Bakare A, Gardiner RJ. Propylthiouracil Disposition in Pregnant and Post-partum Women. <i>Pharmacology</i>. 1982;25(1):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/7122691/pubmed" id="7122691" target="_blank">7122691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-583267">
<a name="583267"></a>Sitar DS, Abu-Bakare A, Gardiner RJ, et al. Effect of Chronic Therapy With Propylthiouracil on its Disposition in Hyperthyroid Patients. <i>Clin Invest Med</i>. 1979;2(2-3):93-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/583267/pubmed" id="583267" target="_blank">583267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1424898">
<a name="1424898"></a>Stankus SJ, Johnson NT. Propylthiouracil-Induced Hypersensitivity Vasculitis Presenting as Respiratory Failure. <i>Chest</i>. 1992;102(5):1595-1596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/1424898/pubmed" id="1424898" target="_blank">1424898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.1">
<a name="REMM.1"></a>US Department of Health and Human Services (HHS) Radiation Emergency Medical Management (REMM). Managing internal radiation contamination. <a href="https://remm.hhs.gov/int_contamination.htm" target="_blank">https://remm.hhs.gov/int_contamination.htm</a>. Accessed February 2, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.2">
<a name="REMM.2"></a>US Department of Health and Human Services (HHS) Radiation Emergency Medical Management (REMM). Propylthiouracil. <a href="https://remm.hhs.gov/propylthiouracil.htm" target="_blank">https://remm.hhs.gov/propylthiouracil.htm</a>. Accessed February 2, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8091264">
<a name="8091264"></a>Westphal SA. Hepatotoxicity From Propylthiouracil. <i>South Med J</i>. 1994;87(9):943-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/8091264/pubmed" id="8091264" target="_blank">8091264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8563481">
<a name="8563481"></a>Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. <i>Thyroid</i>. 1995;5(5):403-405. doi:10.1089/thy.1995.5.403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/8563481/pubmed" id="8563481" target="_blank">8563481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17472842">
<a name="17472842"></a>Yu F, Chen M, Gao Y, et al. Clinical and Pathological Features of Renal Involvement in Propylthiouracil-Associated ANCA-Positive Vasculitis. <i>Am J Kidney Dis</i>. 2007;49(5):607-614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propylthiouracil-drug-information/abstract-text/17472842/pubmed" id="17472842" target="_blank">17472842</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9830 Version 248.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
